Partnered Articles
Writing and Publishing
- BioSpace’s Insights team writes and publishes the article
- Includes up to two subject matter expert interviews of your choosing with BioSpace’s Insights team
- Strategic guidance to optimize your content and demonstrate your thought leadership and subject matter expertise
- Metrics provided after publication
- Social promotion to over 275k BioSpace social followers
- Email promotion in our GenePool newsletter for a week
- Featured on the BioSpace homepage for a week
- Long-term content hosting and SEO benefits
- Creative assets provided
- Includes an Article Reprint so you can further leverage your BioSpace article
BioSpace is the leading platform for life sciences news and careers.
Benefit from BioSpace’s search authority, established media presence and reader loyalty. Elevate your brand and make an impression on key biopharma decision-makers to increase market visibility and stand out from your competitors. BioSpace’s life sciences audience continues to grow, with hundreds of thousands of subscribers, social followers and millions of site visitors, so you can feel confident you’re reaching the right people.
1.25m
average monthly website visits
500k
engaged email subscribers
275k
social followers
10k
new registrations every month
Stem cell therapies vary widely yet many physicians still treat them as interchangeable. A more credible model requires diagnostics, product characterization and conventional medical context to determine who and when should receive regenerative treatment.
With oral cyclic peptides offering small molecule convenience and antibody‑like selectivity, the modality is gaining momentum. But bioavailability below 1%, minimal PK data and fragile synthesis still slow progress. Viva Biotech’s experts outlined how hybrid synthesis, ADME/PK modeling and AI‑guided design are expanding what peptide therapeutics can reach.
Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on understanding disease biology and selecting the right drug candidates to derisk clinical trials.
The shift from ex vivo to in vivo gene delivery is rewriting the rules of viral vector manufacturing, forcing developers to rethink scale, purity, cell lines and analytics as vectors themselves become the drug. AGC Biologics is betting on stable producer lines, next‑gen purification and deeper characterization to meet the far stricter demands of in vivo therapies.
With inspections always on the table, LOTTE Biologics is pushing a proactive, quality first culture across its dual hubs in Syracuse and Songdo, backing its new single‑use ADC facility with rigorous training, self‑audits and real‑time regulatory surveillance.
One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
